Get Ahead of Cancer with Avantect
Changing how and when cancer is
detected with a routine blood test
Get Ahead of Cancer with Avantect
Through a simple blood test, ClearNote Health helps detect cancer early — delivering peace of mind, guiding treatment when it matters most, and transforming how we fight the world’s deadliest diseases.
Join another kind of premiere - one that could save lives.
Join another kind of premiere - one that could save lives.
Many cancers are called “silent killers” because they often develop without symptoms.
Early detection might make all the difference.
Be among the first to know when our Avantect Multi-Cancer Test launches next year – or request Pancreatic or Ovarian Cancer testing, available now.
Learn About Avantect
Learn About Avantect
The Avantect test is a cell-free DNA (cfDNA)-based blood test for patients at high risk for certain cancers. It combines the most advanced epigenomic and genomic science as well as machine learning to detect the presence or absence of an abnormal signal in the blood—providing guidance for a clear plan of action.
ClearNote Health is a cancer detection company focused on enabling longer and healthier lives.
Our tests focus on hard-to-find cancers that have high mortality rates and for which there are currently no or limited detection options – we will revolutionise the treatment of cancer.
Important information
The Avantect Cancer Test is an early detection test. The test does not establish a diagnosis of cancer, and results should be considered in the context of other clinical criteria. Definitive diagnosis of cancer usually requires a series of imaging scans, blood tests, and a biopsy. Not all cancers will be detected. Some patients with cancer may have a “Signal not detected” result. Some patients without cancer may have a “Signal detected” result. False-negative and false-positive results are possible. A “Signal not detected” result does not guarantee that no cancer is present. In some cases, no result is obtained. While this is very uncommon, it may be caused by shipping delays or when there is not enough cell-free DNA for the test in the patient’s blood. If this happens, we generally ask for a repeat blood sample for testing at no extra cost.
The test was developed in the ClearNote Health CLIA-certified (CLIA# 05D2249973) and CAP-accredited (CAP# 9219174) laboratory and has not been cleared or approved by the US Food and Drug Administration (FDA).